Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct

J. W. Yockman, Donghoon Choi, M. G. Whitten, C. W. Chang, A. Kastenmeier, H. Erickson, A. Albanil, M. Lee, S. W. Kim, D. A. Bull

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The development of clinically beneficial myocardial gene therapy has been slowed by reliance on the use of viral carriers and non-physiologic, constitutive gene expression. To specifically address these issues, we have developed a non-viral gene carrier, water-soluble lipopolymer (WSLP), and an ischemia-inducible plasmid construct expressing vascular endothelial growth factor (VEGF), pRTP801-VEGF, to treat myocardial ischemia and infarction. Rabbits underwent ligation of the circumflex artery followed by injection of (a) an ischemia-inducible VEGF gene construct in a WSLP carrier; (b) a constitutively expressed, or unregulated, SV-VEGF gene construct in a WSLP carrier; (c) WSLP carrier alone; or (d) no injection therapy. Following 4 weeks treatment, ligation alone resulted in infarction of 48±7% of the left ventricle. With injection of WSLP carrier alone, 49±6% of the left ventricle was infarcted (P=NS). The constitutively expressed gene construct, SV-VEGF, reduced the infarct size to 32±7% of the left ventricle (P=0.007). The ischemia-inducible gene construct, RTP801-VEGF, further reduced the infarct size to 13±4% of the left ventricle (P<0.001). The use of a non-viral carrier to deliver an ischemia-inducible VEGF construct is effective in the treatment of acutely ischemic myocardium.

Original languageEnglish
Pages (from-to)127-135
Number of pages9
JournalGene Therapy
Volume16
Issue number1
DOIs
Publication statusPublished - 2009 Jan 1

Fingerprint

Vascular Endothelial Growth Factor A
Ischemia
Myocardial Infarction
Apoptosis
Heart Ventricles
Genes
Injections
Ligation
Genetic Therapy
Infarction
Myocardial Ischemia
Myocardium
Plasmids
Therapeutics
Arteries
poly(ethylenimine)-co-(N-(2-aminoethyl) ethyleneimin)-co-N-(N-cholesteryloxycarbonyl-(2-aminoethyl)ethylenimine)
Rabbits
Gene Expression

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Yockman, J. W. ; Choi, Donghoon ; Whitten, M. G. ; Chang, C. W. ; Kastenmeier, A. ; Erickson, H. ; Albanil, A. ; Lee, M. ; Kim, S. W. ; Bull, D. A. / Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct. In: Gene Therapy. 2009 ; Vol. 16, No. 1. pp. 127-135.
@article{23bfbb43a82e4b12b74dafc186fb1c9d,
title = "Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct",
abstract = "The development of clinically beneficial myocardial gene therapy has been slowed by reliance on the use of viral carriers and non-physiologic, constitutive gene expression. To specifically address these issues, we have developed a non-viral gene carrier, water-soluble lipopolymer (WSLP), and an ischemia-inducible plasmid construct expressing vascular endothelial growth factor (VEGF), pRTP801-VEGF, to treat myocardial ischemia and infarction. Rabbits underwent ligation of the circumflex artery followed by injection of (a) an ischemia-inducible VEGF gene construct in a WSLP carrier; (b) a constitutively expressed, or unregulated, SV-VEGF gene construct in a WSLP carrier; (c) WSLP carrier alone; or (d) no injection therapy. Following 4 weeks treatment, ligation alone resulted in infarction of 48±7{\%} of the left ventricle. With injection of WSLP carrier alone, 49±6{\%} of the left ventricle was infarcted (P=NS). The constitutively expressed gene construct, SV-VEGF, reduced the infarct size to 32±7{\%} of the left ventricle (P=0.007). The ischemia-inducible gene construct, RTP801-VEGF, further reduced the infarct size to 13±4{\%} of the left ventricle (P<0.001). The use of a non-viral carrier to deliver an ischemia-inducible VEGF construct is effective in the treatment of acutely ischemic myocardium.",
author = "Yockman, {J. W.} and Donghoon Choi and Whitten, {M. G.} and Chang, {C. W.} and A. Kastenmeier and H. Erickson and A. Albanil and M. Lee and Kim, {S. W.} and Bull, {D. A.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1038/gt.2008.146",
language = "English",
volume = "16",
pages = "127--135",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "1",

}

Yockman, JW, Choi, D, Whitten, MG, Chang, CW, Kastenmeier, A, Erickson, H, Albanil, A, Lee, M, Kim, SW & Bull, DA 2009, 'Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct', Gene Therapy, vol. 16, no. 1, pp. 127-135. https://doi.org/10.1038/gt.2008.146

Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct. / Yockman, J. W.; Choi, Donghoon; Whitten, M. G.; Chang, C. W.; Kastenmeier, A.; Erickson, H.; Albanil, A.; Lee, M.; Kim, S. W.; Bull, D. A.

In: Gene Therapy, Vol. 16, No. 1, 01.01.2009, p. 127-135.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Polymeric gene delivery of ischemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct

AU - Yockman, J. W.

AU - Choi, Donghoon

AU - Whitten, M. G.

AU - Chang, C. W.

AU - Kastenmeier, A.

AU - Erickson, H.

AU - Albanil, A.

AU - Lee, M.

AU - Kim, S. W.

AU - Bull, D. A.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - The development of clinically beneficial myocardial gene therapy has been slowed by reliance on the use of viral carriers and non-physiologic, constitutive gene expression. To specifically address these issues, we have developed a non-viral gene carrier, water-soluble lipopolymer (WSLP), and an ischemia-inducible plasmid construct expressing vascular endothelial growth factor (VEGF), pRTP801-VEGF, to treat myocardial ischemia and infarction. Rabbits underwent ligation of the circumflex artery followed by injection of (a) an ischemia-inducible VEGF gene construct in a WSLP carrier; (b) a constitutively expressed, or unregulated, SV-VEGF gene construct in a WSLP carrier; (c) WSLP carrier alone; or (d) no injection therapy. Following 4 weeks treatment, ligation alone resulted in infarction of 48±7% of the left ventricle. With injection of WSLP carrier alone, 49±6% of the left ventricle was infarcted (P=NS). The constitutively expressed gene construct, SV-VEGF, reduced the infarct size to 32±7% of the left ventricle (P=0.007). The ischemia-inducible gene construct, RTP801-VEGF, further reduced the infarct size to 13±4% of the left ventricle (P<0.001). The use of a non-viral carrier to deliver an ischemia-inducible VEGF construct is effective in the treatment of acutely ischemic myocardium.

AB - The development of clinically beneficial myocardial gene therapy has been slowed by reliance on the use of viral carriers and non-physiologic, constitutive gene expression. To specifically address these issues, we have developed a non-viral gene carrier, water-soluble lipopolymer (WSLP), and an ischemia-inducible plasmid construct expressing vascular endothelial growth factor (VEGF), pRTP801-VEGF, to treat myocardial ischemia and infarction. Rabbits underwent ligation of the circumflex artery followed by injection of (a) an ischemia-inducible VEGF gene construct in a WSLP carrier; (b) a constitutively expressed, or unregulated, SV-VEGF gene construct in a WSLP carrier; (c) WSLP carrier alone; or (d) no injection therapy. Following 4 weeks treatment, ligation alone resulted in infarction of 48±7% of the left ventricle. With injection of WSLP carrier alone, 49±6% of the left ventricle was infarcted (P=NS). The constitutively expressed gene construct, SV-VEGF, reduced the infarct size to 32±7% of the left ventricle (P=0.007). The ischemia-inducible gene construct, RTP801-VEGF, further reduced the infarct size to 13±4% of the left ventricle (P<0.001). The use of a non-viral carrier to deliver an ischemia-inducible VEGF construct is effective in the treatment of acutely ischemic myocardium.

UR - http://www.scopus.com/inward/record.url?scp=58149467652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149467652&partnerID=8YFLogxK

U2 - 10.1038/gt.2008.146

DO - 10.1038/gt.2008.146

M3 - Article

VL - 16

SP - 127

EP - 135

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 1

ER -